Bryanna Tibensky1, Lauren Hutton2, Jason Wentzell3, Michael LeBlanc4, Scott Edwards5, Thomas McFarlane6. 1. , HBSc, PharmD, ACPR, is with the Centre for Family Medicine Family Health Team and the School of Pharmacy, University of Waterloo, Kitchener, Ontario. 2. , BScPharm, ACPR, PharmD, is with Nova Scotia Health and the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia. 3. , BScPhm(Hons), ACPR, BCOP, MHM, is with Extend Pharmacy and Extend Health Solutions, Ottawa, Ontario, and the School of Pharmacy, University of Waterloo, Kitchener, Ontario. 4. , BScPhm, PharmD, FCSHP, is with Horizon Health Network, Moncton, New Brunswick. 5. , BScPhm, PharmD, MSc(Oncology), is with Eastern Health and Memorial University of St John's, Newfoundland and Labrador. 6. , BScPhm, PharmD, is with the School of Pharmacy, University of Waterloo, Kitchener, Ontario.
Abstract
Background: Canadian clinical pharmacy key performance indicators (cpKPIs) have been developed for inpatient hospital practice but are not established for ambulatory oncology. This study represents the first step in developing cpKPIs for ambulatory oncology. Objectives: To describe the current landscape of pharmacy services in ambulatory oncology in Canada and to identify perspectives related to the development and implementation of cpKPIs in this practice setting. Methods: In this national cross-sectional study, a web-based questionnaire was distributed to pharmacists working in ambulatory oncology settings. Potential participants who self-identified as pharmacists practising in an ambulatory oncology setting were eligible. Survey questions focused on participants' demographic characteristics, oncology pharmacy services provided, metrics captured, and pharmacists' perceptions of cpKPIs. All data were analyzed using descriptive statistics. Results: A total of 44 responses were received, with most respondents practising in community hospitals in British Columbia, Ontario, and Atlantic Canada. The services most commonly provided were chemotherapy order verification, laboratory monitoring, identification and resolution of drug therapy problems, and counselling on anticancer medications. Twenty-six of the 44 respondents (59%) indicated that performance metrics or patient outcomes were tracked at their respective institutions, with none being universally captured. Overall, 43 (98%) of the respondents favoured the development of cpKPIs for ambulatory oncology practice. Conclusions: Despite growing patient care needs in ambulatory oncology, there is significant heterogeneity in the scope of pharmacy services offered and the outcomes used to qualify their impact within this setting across Canada. This study demonstrates a clear need for national consensus cpKPIs to inform pharmacy resource utilization and patient-centred quality improvement initiatives. 2022 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.
Background: Canadian clinical pharmacy key performance indicators (cpKPIs) have been developed for inpatient hospital practice but are not established for ambulatory oncology. This study represents the first step in developing cpKPIs for ambulatory oncology. Objectives: To describe the current landscape of pharmacy services in ambulatory oncology in Canada and to identify perspectives related to the development and implementation of cpKPIs in this practice setting. Methods: In this national cross-sectional study, a web-based questionnaire was distributed to pharmacists working in ambulatory oncology settings. Potential participants who self-identified as pharmacists practising in an ambulatory oncology setting were eligible. Survey questions focused on participants' demographic characteristics, oncology pharmacy services provided, metrics captured, and pharmacists' perceptions of cpKPIs. All data were analyzed using descriptive statistics. Results: A total of 44 responses were received, with most respondents practising in community hospitals in British Columbia, Ontario, and Atlantic Canada. The services most commonly provided were chemotherapy order verification, laboratory monitoring, identification and resolution of drug therapy problems, and counselling on anticancer medications. Twenty-six of the 44 respondents (59%) indicated that performance metrics or patient outcomes were tracked at their respective institutions, with none being universally captured. Overall, 43 (98%) of the respondents favoured the development of cpKPIs for ambulatory oncology practice. Conclusions: Despite growing patient care needs in ambulatory oncology, there is significant heterogeneity in the scope of pharmacy services offered and the outcomes used to qualify their impact within this setting across Canada. This study demonstrates a clear need for national consensus cpKPIs to inform pharmacy resource utilization and patient-centred quality improvement initiatives. 2022 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.
Authors: Elaine Lo; Daniel Rainkie; William M Semchuk; Sean K Gorman; Kent Toombs; Richard S Slavik; David Forbes; Andrea Meade; Olavo Fernandes; Sean P Spina Journal: Can J Hosp Pharm Date: 2016-04-29
Authors: Olavo Fernandes; Sean K Gorman; Richard S Slavik; William M Semchuk; Steve Shalansky; Jean-François Bussières; Douglas Doucette; Heather Bannerman; Jennifer Lo; Simone Shukla; Winnie W Y Chan; Natalie Benninger; Neil J MacKinnon; Chaim M Bell; Jeremy Slobodan; Catherine Lyder; Peter J Zed; Kent Toombs Journal: Ann Pharmacother Date: 2015-03-16 Impact factor: 3.154
Authors: V Escudero-Vilaplana; A Ribed; R M Romero-Jimenez; A Herranz-Alonso; M Sanjurjo-Saez Journal: Eur J Cancer Care (Engl) Date: 2016-02-12 Impact factor: 2.520
Authors: Jay M Patel; Lisa M Holle; Jessica M Clement; Thomas Bunz; Christopher Niemann; Kevin W Chamberlin Journal: J Oncol Pharm Pract Date: 2015-10-22 Impact factor: 1.809
Authors: Sven Simons; Susanne Ringsdorf; Michael Braun; Ulrich J Mey; Peter F Schwindt; Yon D Ko; Ingo Schmidt-Wolf; Walther Kuhn; Ulrich Jaehde Journal: Support Care Cancer Date: 2010-06-16 Impact factor: 3.603